Columbia Business School

Northwestern University

Senior executive, consultant and advisor to companies in the life sciences


Princeton Capital Advisors (”PCA”) is the life sciences transaction advisory affiliate of the Albright Stonebridge Group (ASG), the leading global geopolitical consulting firm.  PCA leverages ASG’s broad global network, providing clients with unbiased, sector-specific advice for their most critical strategic decisions.  PCA is focused on serving the specific needs of both large and mid-market biopharma companies on international M&A, licensing and capital transactions.  The team has decades of executive-level management experience at both large and startup pharma and biotechnology companies, and a successful track record in completing hundreds of M&A, equity and debt transactions across the world.  Our global relationships also provide clients with market-leading insights from our on-the-ground presence in markets worldwide.

Princeton Capital Advisors

Senior Advisor

Amasa Technologies, Inc. is using engineered stem-cell based therapeutics to treat Glioblastoma.  The company's proof-of-concept has been established on mouse models of tumor resections with engineered stem cells that showed residual tumor eradication & overall increase in survival.

Amasa Therapeutics

Chief Executive Officer

CEO (part-time role) for Antyllus Therapeutics, a virtual start-up cardiovascular company that is composed of a highly-experience team of business, drug development, research and clinical experts focused on building an asset-centric and cost-efficient plan to identify and develop therapeutics that have utility in the treatment of abdominal aortic aneurysms (AAA). with the ultimate goal to develop a lead candidate through an early proof-of-concept trial.

Antyllus Therapeutics, Inc.

Recent engagements:
--Commercial strategy and diligence reviews for large, multinational venture capital firm
--Commercial and business strategy support for companies launching new products in a variety of categories, including the following: uterine fibroids, fibrosis-related rare diseases, end-stage renal disease, obesity/pre-diabetes, non-instrument based flow cytometry diagnostics, myocardial perfusion following a heart attack, oncology diagnostics, and digital health/software robotics
--Reimbursement and pricing assessment to support development of product for Graft versus Host Disease (GvHD)
--Commercial roadmap to support launch of microbiome product to address recurrent Clostridium difficile infection

Providing consulting and business advisory support to life sciences companies in the following areas:
--New technology identification, evaluation and assessment	
--Commercialization and growth strategy   
--Product launch, branding and positioning
--Global sales and marketing leadership
--Reimbursement strategy
--Business development, partnership negotiation, and merger/acquisition transactions
--Digital health technology strategy	
--Fund-­raising and exit strategy
For more background information, please visit my website at http://www.ajhiller.com

Hiller Life Sciences Strategies, LLC

Commercial strategy consultant, interim CEO and business advisor to companies in the life sciences

Nuritas is harnessing the transformational power of artificial intelligence (AI) to identify peptides that can enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies.  The Nuritas artificial intelligence platform provides the largest peptide database in the world for our drug hunters to explore, and offers the potential to expand and enhance the scope, efficacy and accuracy of discovery in the biopharmaceutical industry.   Using our drug discovery platform, we can identify peptide sequences, combining them to address structural priorities and characteristics of efficacy, cell penetration, and stability.  We can also chemically optimize them on computers, and in vitro and in vivo in the lab to improve those traits.

Nuritas has created a proprietary portfolio of peptide products. Our breakthrough peptide technology platform has identified millions of peptides, and more than 2000 peptide sequences are included in the Nuritas patent estate.  Novel candidates include an anti-fibrotic compound that offers a novel MOA to address conditions like NASH, CKD, scleroderma, IPF, and similar areas, and other novel programs with potential applications in inflammatory, metabolic and cardiovascular diseases.

Nuritas

Chief Business Officer

Smith Therapeutics assets were purchased by AZ Therapies in the second half of 2019.  The company was pursuing a unique approach to treating neurodegenerative diseases (NDD) that exploits recent advances in immunotherapy to engineer powerfully immunosuppressive T regulatory lymphocytes (Treg) to shut down the damaging immune responses that cause NDD.  Prior to the acquisition, the company planned to develop a therapeutic platform using a Treg- based approach to treat Progressive Supranuclear Palsy (PSP), which is a common neurodegenerative disease in the elderly and mimics Parkinson's disease (PD).

Smith Therapeutics

Consultant and Business Advisor

Versatope Therapeutics Incorporated is a preclinical-stage biotechnology company solving problems in vaccine potency and therapeutic delivery using a “bacterial factory” nanoparticle technology. These nanoparticles have versatility in their applications and multiple epitopes can be displayed to overcome strain-specific immunity. Versatope is leveraging its technology platform as a single vaccine to protect against multiple strains of influenza. The nanoparticles could also be used to display antibodies, receptors, or enzymes to further expand their application in bioremediation, diagnostics, and therapeutic delivery.

Versatope Therapeutics, Inc.

Business Advisor

ENB Therapeutics is an early-stage oncology company developing therapies to break drug resistance that occurs in over 50% of patients treated with immunotherapy. The company's lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in melanoma animal models.  ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibit metastasis and prolong patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP.  The company is currently seeking funding to support IND filing and clinical proof of concept for this novel, potentially breakthrough therapy.

ENB Therapeutics

Consultant

Inscope Medical Solutions

CEO (part-time role) for ENB Therapeutics (see above for further description of company).

Interim Chief Executive Officer

Geppetto offers an exciting new compilation of digital technologies to address today’s significant challenges in health care.  The company is building software robots that can benefit people.  They talk, listen, understand, engage, assist and educate.  The Avatars that Geppetto builds are contextual conversational characters that serve as virtual assistants, counselors, decision support and data collection tools for patients, physicians, caregivers, and other providers and payers. 

Accomplishments as CBO:
Led team in negotiating partnership with global IT company to develop prototype platform in Parkinson's Disease; drove strategy and positioning that resulted in placement of the company as one of the top entries in the global HealthXL consortium; developed healthcare strategy that resulted in significant engagement discussions with multinational pharma and medical device industry clients

Geppetto Avatars, Inc.

Chief Business Officer/Consultant

Business advisory and strategic consulting input to Ablacor™ Medical Corporation in support of their CircumBlator™ for patients with atrial fibrillation.  This game-changing catheter allows the physician to maintain stable tissue contact throughout the ablation procedure and, with one touch of a button, can generate a complete ablation.  The patent-pending system is designed to reduce health-related costs while making ablation easier, faster, safer and more reliable for millions of patients.

AblaCor Medical Corporation

SciFluor Life Sciences was established as a private-equity backed drug discovery company that introduces fluorine into molecules to create new chemical entities with improved characteristics of potency, selectivity, half-life, and blood-brain barrier penetration.  The company developed compounds in CNS, infectious disease, ophthalmology, pain, and inflammation, and sought partners interested in enriching pipelines, optimizing drug discovery and accelerating clinical development of innovative new therapies.

Accomplishments as CEO:
-- worked with Board to evolve company strategy following initial fundraising 
-- negotiated expanded license agreement with Harvard University 
-- recruited scientific advisory board, management and chemistry team 
-- co-localized lab and management group into new office and lab facilities 
-- worked with team to file IP and begin preclinical development of 13 new compounds; 
-- initiated broad range of partnering discussions (three transactions completed)

SciFluor Life Sciences, LLC

Business Development Consulting at: 
Sci-Fluor, a private equity-backed drug discovery and development company
On-Q-ity, a venture-backed Oncology diagnostics company
Chief Business Officer and Strategic Advisor at Boston Clinical Research Institute (BCRI)
Senior Advisor and project consultant at Align2Action, Inc., a life sciences consulting group
Advisory Board Member at Concordant Rater Systems

Strategic consultant and business advisor to start-up companies

Raised $22M in B-round funding; successfully built team and launched new technology to achieve penetration in 30 prestigious institutions nationwide and 23% compound annual quarterly growth, ultimately achieving exit for sale to medical device subsidiary of Roper Industries, a $5B Fortune 1000 company.

Heartscape Technologies

Supported sales and marketing team and advised on business strategy; company ultimately acquired by West Coast investment banking firm and subsequently spun out privately.

MedPanel, Inc.

Board Member

Member: Portfolio Review Committee, Commercial Management Team, and Corporate Development Steering Committee
Led New Product Marketing group and Cardiovascular Business Unit, including re-branding and re-positioning of six-year-old acute anti-platelet product (Integrilin); launched new sales force and realigned existing sales force, driving annual product revenues by more than 2x

Millennium Pharmaceuticals

Senior Vice President

Led Global Marketing Teams to support Merck hospital products worldwide, including global launch of anti-platelet (Aggrastat), pre-launch of novel anti-fungal (Cancidas) and anti-infective (Invanz), and ongoing marketing of injectable antibiotic (Primaxin/Tienam)

Merck & Co.

Vice President, Worldwide Human Health Marketing

Played key role in conceptualizing and negotiating five Medco disease management alliances and one joint venture with major pharma manufacturers; led global managed care initiatives for Merck.

Senior Vice President, Business Development

Medical Marketing Group

Executive Vice President

Privately held clinical marketing and medical education business; played key role in expanding revenue base by more than 3X with 16 multinational pharmaceutical clients over 5 years; launched successful Canadian affiliate

MEDED Health Care

Joined as Senior Product Manager, New Products, including products for diabetic complications, dementia, an NSAID, and a new cardiovascular product.  Moved to Licensing and Acquisition, and ultimately to Group Product Director, Diversified Ethicals, which included Premarin.

Arthur Hiller